ABBV vs ANET: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Arista Networks, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-24.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
Arista Networks, Inc. · Technology
$203.47
+15.4% upside to fair value
Med Conviction
Grade C
High Quality
QuantHub Verdict
ANET has more upside to fair value
(+15.4%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
ANET |
| Current Price |
$261.70 |
$203.47 |
| Fair Value Estimate |
$259.04 |
$234.80 |
| Upside to Fair Value |
-1.0%
|
+15.4%
|
| Market Cap |
$462.4B |
$256.2B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
49.7x
|
| Price / Sales |
7.2x
|
24.3x
|
| Price / FCF |
23.6x
|
49.7x
|
| Revenue Growth YoY |
+10.2%
|
+37.7%
|
| Gross Margin |
71.5%
|
63.0%
|
| Operating Margin |
29.3%
|
43.1%
|
| Return on Equity |
-136.5%
|
30.8%
|
| Dividend Yield |
2.61% |
0% |
| FCF Yield |
4.25%
|
2.01%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
Arista Networks designs and sells high-performance Ethernet switching and routing hardware plus its extensible EOS network operating system, and it sits directly in the path of the AI data-center build-out where networking, not compute, is increasingly the bottleneck. The business quality is genuinely high: TTM gross margin of 63.0%, TTM operating margin of 43.1%, TTM net margin of 38.4%, and ROE…
Accumulation Zones
| Metric |
ABBV |
ANET |
| Zone Low |
$194.28 |
$176.10 |
| Zone High |
$220.18 |
$199.58 |
| In Buy Zone? |
No
|
No
|